ÁøÇ༺ ´ëÀåÁ÷Àå¾Ï ȯÀÚ±º¿¡ ÀÖ¾î¼ 5-FU ȤÀº capecitabineÀÇ ÃÖÀû ½Ã°£ Ä¡·á¹ý¿¡ ´ëÇÑ Ã¼°èÀû °íÂû : ¸ÞŸºÐ¼®
5-FU or capecitabine based chronomodulated chemotherapy for advanced colorectal cancer: mata-analysis and systematic review
´ëÇѾÏÇÑÀÇÇÐȸÁö 2015³â 20±Ç 1È£ p.31 ~ p.44
ÀÌÁö¿µ(Lee Ji-Young) - °µ¿°æÈñ´ëÇб³º´¿ø Çѹæ¾Ï¼¾ÅÍ Çѹ泻°ú
¿ÀÇý°æ(Oh Hye-Kyung) - °µ¿°æÈñ´ëÇб³º´¿ø Çѹæ¾Ï¼¾ÅÍ Çѹ泻°ú
·ùÇѼº(Ryu Han-Sung) - °µ¿°æÈñ´ëÇб³º´¿ø Çѹæ¾Ï¼¾ÅÍ Çѹ泻°ú
À±¼º¿ì(Yun Seong-Woo) - °µ¿°æÈñ´ëÇб³º´¿ø Çѹæ¾Ï¼¾ÅÍ Çѹ泻°ú
Abstract
Background : The purpose of this study is to investigate the efficacy and safety of the circadian delivery schedule of fluorouracil or capecitabine based chemotherapy for advanced colorectal cancer.
Patients and methods : A meta-analysis was performed using individual data from eight international randomized clinical trials, especially phase II or III trials, comparing 5-fluorouracil, or capeticabine in chronomodulated or conventional schedule. The data from 8 studies was composed of 692 patients receiving chronomodulated chemotheray and 684 patients receiving conventional chemotherapy. The main end point was response rate.
Results : Response rate was insignificantly different from each group (RR 1.14, 95%CI 0.74-1.74, p=0.55). Overall survival and progresseion-free survival were not significant either. Chemotherapy induced anemia, diarrhea, and nausea/vomiting were worse in the chronotherapy group, with statistic significance respectively. On the other hand, chemotherapy induced thrombocytopenia, stomatitis, peripheral neuropathy, and dermatotoxicity were better but they were not statistically significant results.
Conclusions : Patients lived longer but not significantly on chronomodulated chemotherapy rather than on conventional chemotherapy. Patients on chronomodulated chemotherapy experienced adverse events more. The chronomodulated chemotherapy schedule needs adjustment of its delivery schedule and further research is required.
Å°¿öµå
Chronotherapy , circadian rhythm , 5-FU , capecitabine , advanced colorectal cancer of gastric cancer
KMID :
1191520150200010031
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Response rate was insignificantly different from each group (RR 1.14, 95%CI 0.74-1.74, p=0.55). Overall survival and progresseion-free survival were not significant either.